Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors like Olaparib and histone deacetylase inhibitors like Chidamide show promise in lung cancer treatment.
• The potential synergistic effect of combining Olaparib and Chidamide in lung cancer has not been previously investigated.

Purpose of the Study:

• To investigate the synergistic effect of Olaparib in combination with Chidamide in lung cancer cell lines.
• To elucidate the underlying molecular mechanisms responsible for the observed synergistic effects.

Main Methods:

• Lung cancer cell lines were treated with Olaparib alone or in combination with Chidamide, both in vitro and in vivo.
• Gene expression levels of MYBL2, BRCA1, and cell cycle proteins were analyzed.
• Cell apoptosis and cell cycle progression were assessed.

Main Results:

• A synergistic antitumor effect was observed when Olaparib and Chidamide were used in combination.
• The combined treatment cooperatively downregulated MYBL2 expression, leading to reduced BRCA1 expression and impaired DNA damage repair.
• Olaparib-induced PARP inhibition resulted in synthetic lethality, while MYBL2 downregulation contributed to G2M cell cycle arrest.

Conclusions:

• The combination of Olaparib and Chidamide exhibits synergistic anticancer activity in lung cancer.
• This synergistic effect is mediated by the induction of synthetic lethality via PARP inhibition and cell cycle arrest through MYBL2 and cell cycle protein regulation.
• Combined Olaparib and Chidamide therapy holds potential for enhanced lung cancer treatment.